ARA-290 (Cibinetide)

WHAT IT IS

ARA-290, also known by the generic-style name cibinetide, is a synthetic peptide that mimics a specific helical loop of erythropoietin, the hormone best known for stimulating red blood cell production.

Researchers designed it to interact with what is often described as an innate repair receptor, a complex distinct from the classical erythropoietin receptor that drives blood cell formation, in an attempt to separate tissue-protective signaling from hematopoietic effects.

It has been developed by a small biotechnology company (Araim Pharmaceuticals) and tested in a limited number of investigator-initiated and sponsor trials. It is an investigational compound, not an approved medication.

WHAT RESEARCHERS ARE STUDYING IT FOR

Published human and preclinical research has looked at:

• Neuropathic pain associated with sarcoidosis-related small fiber neuropathy
• Painful diabetic neuropathy symptoms in small pilot trials
• Corneal nerve fiber and epithelial healing in early studies
• General inflammation and metabolic markers in short human trials
• Cytoprotective signaling in animal models of tissue injury

PROPOSED BIOLOGICAL MECHANISMS

The central hypothesis is that ARA-290 activates the innate repair receptor, a complex thought to involve the erythropoietin receptor paired with the common beta receptor subunit (CD131), triggering cell-protective and anti-inflammatory signaling without meaningfully activating the classical erythropoietin pathway.

In small fiber neuropathy research, the interest is whether this signaling can support nerve fiber density or function, which is measured in some trials through skin biopsy nerve counts.

These mechanisms are drawn from a mix of preclinical work and a small number of controlled human studies, not from a large or fully settled body of evidence.

AREAS OF RESEARCH INTEREST

• Whether separating tissue protection from red blood cell stimulation is achievable with a peptide fragment
• Whether ARA-290 meaningfully improves neuropathic pain scores beyond placebo in larger trials
• Long-term safety across repeated dosing
• Which specific neuropathy or inflammatory conditions, if any, show the most consistent signal

WHAT THE EVIDENCE CURRENTLY SUGGESTS

ARA-290 is one of the few compounds on this list with actual human trial data, including small randomized, placebo-controlled studies in sarcoidosis-associated neuropathy and painful diabetic neuropathy. Some of these reported improvements in pain measures and, in one sarcoidosis trial, increased corneal nerve fiber density.

These trials have generally been small, short in duration and run by a limited number of research groups, so the findings should be read as promising early signals rather than established clinical efficacy.

No large, confirmatory phase 3 trial has established ARA-290 as an effective treatment for any condition. FDA status: ARA-290 (cibinetide) is not FDA-approved for any indication.